Endogenous 28-amino-acid thymic peptide; generic medicine name thymalfasin
PRODUCT PROFILE
Thymosin Alpha-1
£69.00
Thymosin Alpha-1 is endogenous 28-amino-acid thymic peptide; generic medicine name thymalfasin. Researchers examine it in relation to dendritic-cell, t-cell and innate immune-response regulation.
Why it is distinct
An immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
- Evidence stageEstablished
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Thymosin Alpha-1 is endogenous 28-amino-acid thymic peptide; generic medicine name thymalfasin. Researchers examine it in relation to dendritic-cell, t-cell and innate immune-response regulation.
Research focus+
Researchers study how it helps immune cells coordinate responses to infection and other challenges. Authorised medical versions exist in some countries, but availability and approved uses vary.
How the mechanism differs+
Modulates Toll-like-receptor-linked and adaptive immune signalling rather than directly killing microbes.
Evidence and limitations+
Human trials exist across immune and infectious-disease settings; authorised status is country- and indication-specific.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study how it helps immune cells coordinate responses to infection and other challenges. Authorised medical versions exist in some countries, but availability and approved uses vary.
Modulates Toll-like-receptor-linked and adaptive immune signalling rather than directly killing microbes.
An immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
Human trials exist across immune and infectious-disease settings; authorised status is country- and indication-specific.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Bronchogen
£46.0020 mgBatch file pendingAirway-tissue focus rather than VIP’s defined VPAC-receptor bronchodilatory biology.
UnavailableAsk about availability -
Early human evidence
LL-37
£59.005 mgBatch file pendingDirect antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
UnavailableAsk about availability -
Experimental
Vilon
£46.0020 mgBatch file pendingA minimal dipeptide bioregulator, much smaller and less mechanistically defined than thymosin alpha-1.
UnavailableAsk about availability -
Clinical research
VIP
Price range: £29.99 through £38.995 mgBatch file pendingA receptor-defined pleiotropic neuropeptide with direct vasodilatory and bronchodilatory effects.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page